ID   NZM004
AC   CVCL_D831
SY   NZM04; NZM4
DR   BioSample; SAMN07624445
DR   BioSample; SAMN14558315
DR   cancercelllines; CVCL_D831
DR   CBA; CBA-1390
DR   Cosmic; 2007645
DR   Cosmic; 2141925
DR   IARC_TP53; 14964
DR   Wikidata; Q54931572
RX   CelloPub=CLPUB00227;
RX   PubMed=7999427;
RX   PubMed=11216673;
RX   PubMed=20041153;
RX   PubMed=21912889;
RX   PubMed=23658559;
RX   PubMed=23755070;
RX   PubMed=24455489;
RX   PubMed=32567790;
CC   Doubling time: 29.8 hours (CelloPub=CLPUB00227); 48 hours (CBA=CBA-1390).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Pro (c.721T>C); ClinVar=VCV000376664; Zygosity=Unspecified (PubMed=11216673; PubMed=21912889).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): CBA=CBA-1390; PubMed=32567790
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11,13
ST   D16S539: 11,12
ST   D18S51: 15 (CBA=CBA-1390)
ST   D18S51: 15,20 (PubMed=32567790)
ST   D19S433: 12,15
ST   D21S11: 29,30
ST   D2S1338: 17,19
ST   D3S1358: 15,18
ST   D5S818: 9
ST   D7S820: 8,9
ST   D8S1179: 10,13
ST   FGA: 23,24
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 15
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 20
//
RX   CelloPub=CLPUB00227;
RA   Daukste L.;
RT   "Mathematical modelling of cancer cell population dynamics.";
RL   Thesis PhD (2012), University of Canterbury, New Zealand.
//
RX   PubMed=7999427; DOI=10.1016/0959-8049(94)90188-0;
RA   Marshall E.S., Matthews J.H.L., Shaw J.H.F., Nixon J., Tumewu P.,
RA   Finlay G.J., Holdaway K.M., Baguley B.C.;
RT   "Radiosensitivity of new and established human melanoma cell lines:
RT   comparison of [3H]thymidine incorporation and soft agar clonogenic
RT   assays.";
RL   Eur. J. Cancer 30:1370-1376(1994).
//
RX   PubMed=11216673; DOI=10.3727/096504001108747620;
RA   Parmar J., Marshall E.S., Charters G.A., Holdaway K.M., Shelling A.N.,
RA   Baguley B.C.;
RT   "Radiation-induced cell cycle delays and p53 status of early passage
RT   melanoma cell lines.";
RL   Oncol. Res. 12:149-155(2000).
//
RX   PubMed=20041153; DOI=10.1371/journal.pone.0008461;
RA   Jeffs A.R., Glover A.C., Slobbe L.J., Wang L., He S.-J., Hazlett J.A.,
RA   Awasthi A., Woolley A.G., Marshall E.S., Joseph W.R., Print C.G.,
RA   Baguley B.C., Eccles M.R.;
RT   "A gene expression signature of invasive potential in metastatic
RT   melanoma cells.";
RL   PLoS ONE 4:E8461-E8461(2009).
//
RX   PubMed=21912889; DOI=10.1007/s10637-011-9744-z;
RA   Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A.,
RA   Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P.,
RA   Ding A., Baguley B.C.;
RT   "Therapeutic reactivation of mutant p53 protein by quinazoline
RT   derivatives.";
RL   Invest. New Drugs 30:2035-2045(2012).
//
RX   PubMed=23658559; DOI=10.3389/fgene.2013.00066;
RA   Stones C.J., Kim J.E., Joseph W.R., Leung E.Y., Marshall E.S.,
RA   Finlay G.J., Shelling A.N., Baguley B.C.;
RT   "Comparison of responses of human melanoma cell lines to MEK and BRAF
RT   inhibitors.";
RL   Front. Genet. 4:66.1-66.6(2013).
//
RX   PubMed=23755070; DOI=10.3389/fgene.2013.00097;
RA   Kim J.E., Leung E.Y., Baguley B.C., Finlay G.J.;
RT   "Heterogeneity of expression of epithelial-mesenchymal transition
RT   markers in melanocytes and melanoma cell lines.";
RL   Front. Genet. 4:97.1-97.8(2013).
//
RX   PubMed=24455489; DOI=10.3389/fonc.2013.00333;
RA   D'mello S.A.N., Flanagan J.U., Green T.N., Leung E.Y.,
RA   Askarian-Amiri M.E., Joseph W.R., McCrystal M.R., Isaacs R.J.,
RA   Shaw J.H.F., Furneaux C.E., During M.J., Finlay G.J., Baguley B.C.,
RA   Kalev-Zylinska M.L.;
RT   "Evidence that GRIN2A mutations in melanoma correlate with decreased
RT   survival.";
RL   Front. Oncol. 3:333.1-333.9(2014).
//
RX   PubMed=32567790; DOI=10.1111/pcmr.12908;
RA   Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J.,
RA   Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S.,
RA   Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.;
RT   "Genomic and signalling pathway characterization of the NZM panel of
RT   melanoma cell lines: a valuable model for studying the impact of
RT   genetic diversity in melanoma.";
RL   Pigment Cell Melanoma Res. 34:136-143(2021).
//